population pharmacokinetic study in patients with normal or impaired liver functions, receiving paclitaxel for cancer treatment.~40 Patients with histologically confirmed solid tumors will be enrolled in the study:~20 patients have normal liver functions as defined by transaminase < 2.6 x ULN and bilirubin values < 1.26 x ULN.~20 patients with liver impairment as defined by transaminase 2.6 - 10 x ULN and bilirubin values 1.26 - 5 x ULN.
The study aims to assess the pharmacokinetics of paclitaxel and its two major metabolites in patients with normal and impaired liver functions.